Skip to content
2000
image of Impact of Statin Therapy on Mortality and Rehospitalization in Acute Heart Failure Patients Stratified by Ejection Fraction: Insights from the Gulf CARE Registry

Abstract

Background

The prevalence and clinical outcomes of statin therapy in patients with acute heart failure [AHF] stratified by left ventricular ejection fraction [EF] in the Middle East are unknown.

Methods

We analysed 5005 patients admitted to 47 hospitals in seven Middle Eastern countries [Saudi Arabia, Oman, Yemen, Kuwait, United Arab Emirates, Qatar, and Bahrain] with AHF from February to November 2012 with AHF who were enrolled in Gulf CARE, a multinational registry of patients with heart failure [HF]. AHF patients were stratified into three groups: HF patients with reduced [EF] [HFrEF] [<40%], HF with mildly reduced EF [HFmrEF] [40-49%], and HF patients with preserved EF [HFpEF] [≥50%].

Results

The mean age of the cohort was 59.3±14.9 years, 62.6% [n=3131.0] of the patients were males. A total of 2555 [51%] AHF patients had used statins prior to hospital admission. The mean EF was 36.9±14%. HFrEF was observed in 2683 patients [53%], whereas 961 patients [19.2%] had HFmrEF, and 932 patients [18.6%] had HFpEF. Multivariate logistic regression analysis revealed that prior statin use was significantly associated with reduced in-hospital mortality risk [OR=1.43, 95% CI: 1.10-1.86, p=0.007] and hospitalization rates for heart failure [OR=0.71, 95% CI: 0.60-0.83, p<0.001]. However, when examining rates of survival, there were no significant disparities between the two groups; at 3 months follow-up: aOR, 1.22; 95% Cl: 0.95-1.57; P=0.111; and 12-months follow-up: aOR, 1.07; 95% Cl: 1.07 0.87-1.31; P=0.553. Regarding rehospitalization rates, no significant difference was observed at a 3-month follow-up: aOR, 1.22; 95% Cl: 1.03-1.42; P=0.015. Interestingly, patients admitted with statin therapy were significantly associated with higher odds of hospitalization during the 12-month follow-up period: aOR, 1.42; 95% Cl: 1.21-1.66; P<0.001.

Conclusion

Prior statin use was associated with a lower risk of in-hospital mortality and re-hospitalization. However, there were no significant differences in all-cause mortality between the two groups at both 3- and 12-month follow-ups. While rehospitalization rates at the 3-month follow-up showed higher odds of rehospitalization at the 12-month follow-up. Prior statin therapy appears to influence both in-hospital mortality and long-term rehospitalization outcomes in a Middle Eastern patient population.

Loading

Article metrics loading...

/content/journals/cvp/10.2174/0115701611311671250416054455
2025-04-30
2025-09-25
Loading full text...

Full text loading...

References

  1. Malik A. Brito D. Vaqar S. Chhabra L. Congestive heart failure. Treasure Island, FL StatPearls 2023
    [Google Scholar]
  2. Levy D. Kenchaiah S. Larson M.G. Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 2002 347 18 1397 1402 10.1056/NEJMoa020265 12409541
    [Google Scholar]
  3. Kannel W.B. Dawber T.R. Friedman G.D. Glennon W.E. McNamara P.M. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; The framingham study. Ann. Intern. Med. 1964 61 5_Part_1 888 899 10.7326/0003‑4819‑61‑5‑888 14233810
    [Google Scholar]
  4. Charach G. Argov O. Nochomovitz H. Rogowski O. Charach L. Grosskopf I. A longitudinal 20 years of follow up showed a decrease in the survival of heart failure patients who maintained low LDL cholesterol levels. QJM 2018 111 5 319 325 10.1093/qjmed/hcy043 29733423
    [Google Scholar]
  5. Caravaca R.J.M. Pastor E.M.A. Heart failure and cardiac events: Is a consecutive measurement of biomarkers a simple and practical approach? Thromb. Haemost. 2019 119 12 1891 1893 10.1055/s‑0039‑3400274 31805599
    [Google Scholar]
  6. Benjamin E.J. Blaha M.J. Chiuve S.E. Cushman M. Das S.R. Deo R. Heart disease and stroke statistics—2017 update: A report from the American heart association. Circulation 2017 135 10 e146 e603
    [Google Scholar]
  7. Pignone M. Phillips C. Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: Meta-analysis of randomised trials. BMJ 2000 321 7267 983 986 10.1136/bmj.321.7267.983 11039962
    [Google Scholar]
  8. Paulus W.J. Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 2013 62 4 263 271 10.1016/j.jacc.2013.02.092 23684677
    [Google Scholar]
  9. Tsuda K. Kataoka Y. Ogata S. Diminished response to statins predicts the occurrence of heart failure after acute myocardial infarction. Cardiovasc. Diagn. Ther. 2020 10 4 705 716 10.21037/cdt‑20‑415 32968627
    [Google Scholar]
  10. Jacobs J.A. Addo D.K. Zheutlin A.R. Prevalence of statin use for primary prevention of atherosclerotic cardiovascular disease by race, ethnicity, and 10-year disease risk in the US: National health and nutrition examination surveys, 2013 to March 2020. JAMA Cardiol. 2023 8 5 443 452 10.1001/jamacardio.2023.0228 36947031
    [Google Scholar]
  11. Sulaiman K. Panduranga P. Zakwani A.I. Rationale, design, methodology and hospital characteristics of the first gulf acute heart failure registry (gulf care). Heart Views 2014 15 1 6 12 10.4103/1995‑705X.132137 24949181
    [Google Scholar]
  12. Sulaiman K. Panduranga P. Zakwani A.I. Clinical characteristics, management, and outcomes of acute heart failure patients: Observations from the Gulf acute heart failure registry (Gulf CARE). Eur. J. Heart Fail. 2015 17 4 374 384 10.1002/ejhf.245 25739882
    [Google Scholar]
  13. Jarallah A.M. Rajan R. Zakwani A.I. Incidence and impact of cardiorenal anaemia syndrome on all‐cause mortality in acute heart failure patients stratified by left ventricular ejection fraction in the Middle East. ESC Heart Fail. 2019 6 1 103 110 10.1002/ehf2.12351 30315634
    [Google Scholar]
  14. Jarallah A.M. Rajan R. Zakwani A.I. Impact of diabetes on mortality and rehospitalization in acute heart failure patients stratified by ejection fraction. ESC Heart Fail. 2020 7 1 298 306 10.1002/ehf2.12538 31825180
    [Google Scholar]
  15. Jarallah A.M. Rajan R. Heshmat H. Zakwani A.I. Dashti R. Bulbanat B. Comparison of demographics and outcomes of acute heart failure patients with reduced, mid range, and preserved ejection fraction. Annal Clin Cardiol 2020 2 2 86 94
    [Google Scholar]
  16. Ponikowski P. Voors A.A. Anker S.D. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016 37 27 2129 2200 10.1093/eurheartj/ehw128 27206819
    [Google Scholar]
  17. Dickstein K. Solal C.A. Filippatos G. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the european society of intensive care medicine (ESICM). Eur. Heart J. 2008 29 19 2388 2442 10.1093/eurheartj/ehn309 18799522
    [Google Scholar]
  18. Paulus W.J. Tschöpe C. Sanderson J.E. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the european society of cardiology. Eur. Heart J. 2007 28 20 2539 2550 10.1093/eurheartj/ehm037 17428822
    [Google Scholar]
  19. McMurray J.J.V. Adamopoulos S. Anker S.D. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur. Heart J. 2012 33 14 1787 1847 10.1093/eurheartj/ehs104 22611136
    [Google Scholar]
  20. Yancy C.W. Jessup M. Bozkurt B. ACCF/AHA Guideline for the management of heart failure: A report of the american college of cardiology Foundation/American heart association task force on practice guidelines. Circulation 2013 128 16 e240 e327 10.1161/CIR.0b013e31829e8776 23741058
    [Google Scholar]
  21. Tilson M.D. III The polymorphonuclear leukocyte and the abdominal aortic aneurysm: A neglected cell type and a neglected disease. Circulation 2005 112 2 154 156 10.1161/CIRCULATIONAHA.105.553370 16009807
    [Google Scholar]
  22. Stancu C. Sima A. Statins: Mechanism of action and effects. J. Cell. Mol. Med. 2001 5 4 378 387 10.1111/j.1582‑4934.2001.tb00172.x 12067471
    [Google Scholar]
  23. Sizar O. Khare S. Jamil R.T. Talati R. Statin medications. Treasure Island, FL StatPearls 2023
    [Google Scholar]
  24. Antonopoulos A.S. Margaritis M. Lee R. Channon K. Antoniades C. Statins as anti-inflammatory agents in atherogenesis: Molecular mechanisms and lessons from the recent clinical trials. Curr. Pharm. Des. 2012 18 11 1519 1530 10.2174/138161212799504803 22364136
    [Google Scholar]
  25. Jeffrey L. Impact of statin therapy in heart failure patients. Results of a Large Real-World Experience JACC Adv 2023 2 4 100385 38938227
    [Google Scholar]
  26. Lo H.Y. Association of statin therapy with major adverse cardiovascular and limb outcomes in patients with end-stage kidney disease and peripheral artery disease receiving maintenance dialysis. JAMA Netw. Open 2022 5 9 e2229706 10.1001/jamanetworkopen.2022.29706 36048442
    [Google Scholar]
  27. Couto R.M. Terra P.P. Santos Q.J. Pereira S.C. Teixeira A.A. Sousa T. Inflammation in human heart failure: Major mediators and therapeutic targets. Front. Physiol. 2021 12 746494 10.3389/fphys.2021.746494 34707513
    [Google Scholar]
  28. Dabrowa B.A. Bytyçi I. Haehling V.S. Association of statin use and clinical outcomes in heart failure patients: A systematic review and meta-analysis. Lipids Health Dis. 2019 18 1 188 10.1186/s12944‑019‑1135‑z 31672151
    [Google Scholar]
  29. Rogers J.K. Jhund P.S. Perez A.C. Effect of rosuvastatin on repeat heart failure hospitalizations: The CORONA trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail. 2014 2 3 289 297 10.1016/j.jchf.2013.12.007 24952697
    [Google Scholar]
  30. Tavazzi L. Maggioni A.P. Marchioli R. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008 372 9645 1231 1239 10.1016/S0140‑6736(08)61240‑4 18757089
    [Google Scholar]
  31. Sivkov A. Chernus N. Gorenkov R. Sivkov S. Sivkova S. Savina T. Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia. Lipids Health Dis. 2021 20 1 157 10.1186/s12944‑021‑01586‑7 34749751
    [Google Scholar]
  32. Nanna M.G. Navar A.M. Zakroysky P. Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use. JAMA Cardiol. 2018 3 8 739 748 10.1001/jamacardio.2018.1511 29898219
    [Google Scholar]
  33. Coleman C.I. Kluger J. Bhavnani S. Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction. Heart Rhythm 2008 5 4 507 510 10.1016/j.hrthm.2007.12.023 18362016
    [Google Scholar]
  34. Alehagen U. Benson L. Edner M. Dahlström U. Lund L.H. Association between use of statins and mortality in patients with heart failure and ejection fraction of ≥50%. Circ. Heart Fail. 2015 8 5 862 870 10.1161/CIRCHEARTFAILURE.115.002143 26243795
    [Google Scholar]
  35. Alehagen U. Benson L. Edner M. Dahlström U. Lund L.H. Association between use of statins and outcomes in heart failure with reduced ejection fraction: Prospective propensity score matched cohort study of 21 864 patients in the swedish heart failure registry. Circ. Heart Fail. 2015 8 2 252 260 10.1161/CIRCHEARTFAILURE.114.001730 25575580
    [Google Scholar]
  36. Hayıroğlu M.İ. Şaylık F. Çınar T. Tokgözoğlu L. Meta-analysis of the current research on the relationship between blood lipid levels and the occurrence of atrial fibrillation. Heart Lung Circ. 2023 32 10 1158 1166 10.1016/j.hlc.2023.08.006 37741751
    [Google Scholar]
  37. Özdemir T. Şahin İ. Avcı İ.İ. Assessment of factors related to statin non-adherence in patients with established coronary artery disease: A single-center observational study. Turk Kardiyol. Dern. Ars. 2017 45 8 723 730 10.5543/tkda.2017.89947 29226893
    [Google Scholar]
/content/journals/cvp/10.2174/0115701611311671250416054455
Loading
/content/journals/cvp/10.2174/0115701611311671250416054455
Loading

Data & Media loading...


  • Article Type:
    Research Article
Keywords: mortality ; Heart failure hospitalization ; Statin therapy ; Middle East ; acute heart failure
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test